GB1292197A - Method for the disruption of viruses - Google Patents

Method for the disruption of viruses

Info

Publication number
GB1292197A
GB1292197A GB2275770A GB2275770A GB1292197A GB 1292197 A GB1292197 A GB 1292197A GB 2275770 A GB2275770 A GB 2275770A GB 2275770 A GB2275770 A GB 2275770A GB 1292197 A GB1292197 A GB 1292197A
Authority
GB
United Kingdom
Prior art keywords
viruses
disrupted
aqueous medium
wetting agent
polyoxyethylene sorbitan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB2275770A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Publication of GB1292197A publication Critical patent/GB1292197A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GB2275770A 1969-05-16 1970-05-12 Method for the disruption of viruses Expired GB1292197A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82678369A 1969-05-16 1969-05-16

Publications (1)

Publication Number Publication Date
GB1292197A true GB1292197A (en) 1972-10-11

Family

ID=25247524

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2275770A Expired GB1292197A (en) 1969-05-16 1970-05-12 Method for the disruption of viruses

Country Status (3)

Country Link
DE (1) DE2023987C3 (enExample)
FR (1) FR2051533B1 (enExample)
GB (1) GB1292197A (enExample)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE661402A (enExample) * 1964-03-20

Also Published As

Publication number Publication date
FR2051533A1 (enExample) 1971-04-09
FR2051533B1 (enExample) 1974-04-12
DE2023987B2 (de) 1978-09-07
DE2023987C3 (de) 1979-05-03
DE2023987A1 (de) 1970-12-17

Similar Documents

Publication Publication Date Title
GB1450557A (en) Adjuvant compositions and medicinal mixtures comprising them
Asano et al. Soluble skin test antigen of varicella-zoster virus prepared from the fluid of infected cultures
BR9106374A (pt) Vacina oral e processo de extrair uma imunoresponsta em um mamifero
PT86376A (en) Process for the preparation of an adjuvant suspension comprising dimethyl dioctadecyl ammonium bromide
Lahelle et al. Hemagglutination with the GDVII strain of mouse encephalomyelitis virus
JPS5538314A (en) Fat emulsion and its preparation
Nagai et al. The pathogenicity of Newcastle disease virus isolated from migrating and domestic ducks and the susceptibility of the viral glycoproteins to proteolytic cleavage
Pulkkinen et al. Plaque size heterogeneity: a genetic trait of lymphocytic choriomeningitis virus
Bro-Jørgensen The interplay between lymphocytic choriomeningitis virus, immune function, and hemopoiesis in mice
GB1292197A (en) Method for the disruption of viruses
GB1256456A (en) Ethylethyleneimine as inactivating agent in antigen-containing pharmaceutical preparations
JPS6314729A (ja) 生ワクチン用改良安定剤、その製造法およびそれを含有するワクチン
IE40794B1 (en) Influenza vaccines
GR3026619T3 (en) Inactivated respiratory syncytial viral vaccines
IE830861L (en) Equine influenza vaccine.
JPS5665841A (en) Purification of lactic acid
US3686394A (en) Attenuated live rubella virus vaccine and method of production
GB1229306A (enExample)
GB1062703A (en) Vaccine compositions
JPS6419023A (en) Heat treatment of fibrinogen and fibrinogen preparation
Melendez et al. Multiplication of foot and mouth disease virus in adult kidney, and embryonic lung and heart bovine tissue cultures
JPS561895A (en) Enzymic determination of monofunctional fatty acid
JPS5242815A (en) Process for preparation of carboxylic acid esters
World Health Organization INSTITUTES MANUFACTURING YELLOW-FEVER VACCINES APPROVED BY WHO1= INSTITUTS PRÉPARANT UN VACCIN ANTIAMARIL AGRÉÉ PAR L’OMS1
Wawrzkiewicz et al. Biological properties of distemper attenuated strain propagated in chick fibroblasts in the medium of own production.

Legal Events

Date Code Title Description
PS Patent sealed
PCNP Patent ceased through non-payment of renewal fee